Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

By W. Foulkes, I. Stefansson, P. Chappuis, L. Bégin, J. Goffin, N. Wong, M. Trudel, L. Akslen. Journal of the National Cancer Institute, 2004

808 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics

View Paper: https://www.semanticscholar.org/paper/7c730c194901b6043c8d69df3c8368c7ed266153

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Genetics

Citations in the corpus

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. (2006, neutral): “Lymph node status Positive 189 (39) 41 (41) 18 (56) 86 (34) 35 (47) 9 (29) .”
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors (2007, background): “The finding that Brca1 loss (coincident with p53 mutation) in mice gives rise to tumors with a basal-like phenotype is notable because humans carrying BRCA1 germline mutations also develop basal-like tumors [3,32], and most human BRCA1 mutant tumors are p53-deficient [43,44].”
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. (2008, background): “A high proportion of BRCA1/2-associated breast carcinomas and those characterized by the basal phenotype overexpress EGFR.”
Deconstructing the molecular portraits of breast cancer (2010, background): “As noted earlier, Basal-like andpotentially Claudin-low tumors, are commonly seen in BRCA1 mutation carriers (Foulkes et al., 2003), and defects in the BRCA1 pathwaymay also be involved in sporadic tumors of both subtypes.”
Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment (2019, background): “Most BRCA1-related tumors are basal-like (91), and there is a marked resemblance in phenotype and biology between sporadic basal-like tumors and BRCA-associated cancers (90).”
Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. (2012, neutral): “Firstly, BLCs represent the majority of breast carcinomas arising in BRCA1 mutation carriers, while representing less than 20% of sporadic breast tumors (2).”
Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype (2007, result): “5%) corresponds well to the reported incidence of the basal-like breast cancer.(12,45,46) Despite these shortcomings, our study is of value because 1) it includes a sufficiently adequate number of breast cancer cases; 2) it reflects real-world experience of a large, statewide cancer registry in an e”
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma (2004, background): “In another recent study, the basal-like subtype, as defined by cytokeratin 5/6 expression by immunohistochemistry (IHC), was also found to be common among breast cancer patients with hereditary BRCA1 mutations (7).”